

Angela Buonadonna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3319799/publications.pdf>

Version: 2024-02-01

160
papers

7,749
citations

94381

37
h-index

53190

85
g-index

167
all docs

167
docs citations

167
times ranked

8941
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1609-1618.	13.9	845
2	Soft tissue and visceral sarcomas: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
3	Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 1238-1247.	0.8	631
4	Gastrointestinal stromal tumours: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
5	Bone sarcomas: ESMOâ€“PaedCanâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
6	The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3061-3068.	0.8	328
7	Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 337-344.	0.8	328
8	Predictive Role of the <i>UGT1A1</i> , <i>UGT1A7</i> , and <i>UGT1A9</i> Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan. <i>Journal of Clinical Oncology</i> , 2009, 27, 2457-2465.	0.8	216
9	Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI. <i>European Journal of Cancer</i> , 1998, 34, 632-640.	1.3	206
10	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
11	Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas. <i>Oncology</i> , 2003, 65, 80-84.	0.9	173
12	Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 866-871.	0.8	156
13	Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1054-1065.	3.0	138
14	Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1385-1394.	0.8	114
15	Prognostic factors in soft tissue sarcomas: a study of 395 patients. <i>European Journal of Surgical Oncology</i> , 2002, 28, 153-164.	0.5	105
16	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , 2018, 29, 924-930.	0.6	99
17	Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. <i>Supportive Care in Cancer</i> , 2011, 19, 1217-1225.	1.0	96
18	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , 2015, 26, 542-547.	0.6	96

#	ARTICLE	IF	CITATIONS
19	Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.. Journal of Clinical Oncology, 1996, 14, 1885-1894.	0.8	95
20	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Annals of Oncology, 2004, 15, 1749-1759.	0.6	90
21	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Annals of Oncology, 2014, 25, 1373-1378.	0.6	84
22	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Annals of Oncology, 2018, 29, 1528-1534.	0.6	83
23	Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies. Annals of Surgical Oncology, 2011, 18, 3686-3693.	0.7	81
24	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. European Journal of Cancer, 2014, 50, 784-792.	1.3	80
25	Clinical validity of a CYP2D6-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. International Journal of Cancer, 2015, 137, 2971-2980.	2.3	70
26	Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Annals of Oncology, 2003, 14, 1135-1141.	0.6	67
27	Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Annals of Oncology, 2014, 25, 1059-1064.	0.6	67
28	Solid pseudopapillary tumour of the pancreas. Lancet Oncology, The, 2003, 4, 255-256.	5.1	54
29	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenetics and Genomics, 2013, 23, 549-557.	0.7	49
30	The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal) cT3 rectal cancer. Radiotherapy and Oncology, 2019, 134, 110-118.	0.3	48
31	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Annals of Oncology, 2016, 27, 843-849.	0.6	46
32	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISGSTS 1001 randomized trial. Cancer, 2022, 128, 85-93.	2.0	46
33	Neoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer, 2011, 72, 340-347.	0.9	44
34	Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. Thrombosis Research, 1995, 78, 127-137.	0.8	42
35	Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of Oncology, 1999, 10, 539-546.	0.6	40
36	Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. PLoS ONE, 2014, 9, e84940.	1.1	40

#	ARTICLE	IF	CITATIONS
37	The Genotype for <i>DPYD</i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 994-1002.	2.3	39
38	Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 918-924.	3.2	35
39	Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2005, 11, 6901-6907.	3.2	34
40	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , 2019, 27, 2425-2434.	1.0	34
41	Cost Evaluation of Irinotecan-Related Toxicities Associated With the <i>UGT1A1*28</i> Patient Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 123-130.	2.3	31
42	HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. <i>PLoS ONE</i> , 2015, 10, e0144000.	1.1	31
43	A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 1157-1165.	0.7	29
44	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. <i>Annals of Oncology</i> , 2003, 14, 843-848.	0.6	27
45	Epirubicin and ifosfamide in advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 1993, 4, 669-672.	0.6	26
46	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. <i>World Journal of Gastroenterology</i> , 2017, 23, 6674-6684.	1.4	26
47	Malignant cardiac tumors: diagnosis and treatment. <i>Future Cardiology</i> , 2015, 11, 485-500.	0.5	25
48	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 336-336.	0.8	25
49	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
50	Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). <i>Molecular Medicine Reports</i> , 2011, 4, 203-8.	1.1	24
51	Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STs) Protocol 0303. <i>Annals of Surgical Oncology</i> , 2017, 24, 3872-3879.	0.7	24
52	Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 367.	1.6	24
53	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
54	Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 13008.	1.6	23

#	ARTICLE	IF	CITATIONS
55	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	1.9	23
56	Probe-based confocal laser endomicroscopy for in vivo evaluation of the tumor vasculature in gastric and rectal carcinomas. <i>Scientific Reports</i> , 2017, 7, 9819.	1.6	22
57	Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. <i>Frontiers in Pharmacology</i> , 2017, 8, 712.	1.6	22
58	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. <i>PLoS ONE</i> , 2019, 14, e0225225.	1.1	21
59	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 661-668.	1.9	21
60	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 878-886.	2.9	20
61	Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. <i>Annals of Oncology</i> , 2005, 16, 716-725.	0.6	18
62	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. <i>Liver International</i> , 2017, 37, 1345-1353.	1.9	18
63	Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. <i>International Journal of Molecular Sciences</i> , 2018, 19, 47.	1.8	17
64	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	1.3	17
65	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-657.	0.8	17
66	Malignant pericardial effusion: sclerotherapy or local chemotherapy?. <i>British Journal of Cancer</i> , 2009, 101, 734-735.	2.9	16
67	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	2.9	15
68	Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin. <i>Cancers</i> , 2020, 12, 1983.	1.7	15
69	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	1.7	15
70	Gastric Cancer with Bone Marrow Invasion at Presentation: Case-Report and Review of the Literature. <i>Tumori</i> , 1995, 81, 74-76.	0.6	14
71	Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response. <i>Annals of Surgical Oncology</i> , 2016, 23, 4302-4309.	0.7	14
72	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. <i>Frontiers in Oncology</i> , 2019, 9, 1312.	1.3	14

#	ARTICLE	IF	CITATIONS
73	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , 2016, 7, 19781-19793.	0.8	14
74	Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors. <i>Tumori</i> , 1999, 85, 229-233.	0.6	13
75	Metastatic Angiosarcoma of the Spleen. A Case Report and Treatment Approach. <i>Tumori</i> , 2001, 87, 439-443.	0.6	13
76	HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1366.	1.8	13
77	A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity. <i>Journal of Personalized Medicine</i> , 2020, 10, 234.	1.1	13
78	Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases. <i>Tumori</i> , 2003, 89, 311-313.	0.6	12
79	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1482.	1.8	12
80	Neoadjuvant Therapy of Rectal Cancer New Treatment Perspectives. <i>Tumori</i> , 2004, 90, 373-378.	0.6	11
81	Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. <i>Sarcoma</i> , 2016, 2016, 1-7.	0.7	11
82	Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer. <i>Cancers</i> , 2019, 11, 880.	1.7	11
83	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. <i>Frontiers in Microbiology</i> , 2019, 10, 475.	1.5	11
84	Continuous Infusion Fluorouracil in the Management of Advanced Breast Cancer: A Phase II Study. <i>Tumori</i> , 2000, 86, 42-45.	0.6	10
85	Exocrine and Endocrine Modulation in Common Gastric Carcinoma. <i>American Journal of Clinical Pathology</i> , 2012, 137, 712-721.	0.4	10
86	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFR Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. <i>Frontiers in Pharmacology</i> , 2020, 11, 36.	1.6	10
87	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. <i>Cancers</i> , 2021, 13, 1705.	1.7	10
88	Morphologic shift associated with aberrant cytokeratin expression in a GIST patient after tyrosine kinase inhibitors therapy. A case report with a brief review of the literature. <i>Pathology Research and Practice</i> , 2016, 212, 63-67.	1.0	9
89	A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach. <i>Cancer Biology and Therapy</i> , 2018, 19, 254-259.	1.5	9
90	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	2.9	9

#	ARTICLE	IF	CITATIONS
91	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. <i>Annals of Oncology</i> , 2007, 18, 1177-1184.	0.6	8
92	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1101.	1.6	8
93	Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems. <i>Oncologist</i> , 2020, 25, e1254-e1254.	1.9	8
94	FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).. <i>Journal of Clinical Oncology</i> , 2010, 28, 3543-3543.	0.8	8
95	Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinicalâ€Biomolecular Markers Significantly Associated With Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 686-696.	2.3	8
96	Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. <i>Cancer Biology and Therapy</i> , 2014, 15, 1439-1443.	1.5	7
97	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	2.9	7
98	Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution. <i>Tumori</i> , 2003, 89, 400-404.	0.6	6
99	Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. <i>International Journal of Clinical Oncology</i> , 2013, 18, 510-516.	1.0	6
100	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. <i>Pharmacogenomics</i> , 2019, 20, 1179-1187.	0.6	6
101	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 30-37.	0.3	6
102	Khorana score and thromboembolic risk in stage IIâ€“III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	1.4	6
103	Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. <i>International Journal of Colorectal Disease</i> , 2014, 29, 639-640.	1.0	5
104	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	1.7	5
105	Systemic Treatments for Advanced Small Bowel Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2022, 14, 1502.	1.7	5
106	Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer. <i>Neoplasia</i> , 2014, 16, 751-756.	2.3	4
107	Fieldâ€Assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma. <i>Journal of Mass Spectrometry</i> , 2017, 52, 283-289.	0.7	4
108	Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 626275.	1.3	4

#	ARTICLE	IF	CITATIONS
109	FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients. <i>Annals of Oncology</i> , 2006, 17, 1606-1607.	0.6	3
110	Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. <i>Cancer Biology and Therapy</i> , 2016, 17, 1017-1021.	1.5	3
111	Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analysis of Tribe and Tribe-2 Studies by GONO. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	3
112	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	1.3	3
113	Ventricular Arrhythmias Due to Glomangiosarcoma Cardiac Metastases. <i>JACC: CardioOncology</i> , 2021, 3, 150-153.	1.7	2
114	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3532-3532.	0.8	2
115	Neoadjuvant epirubicin, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4066-4066.	0.8	2
116	Hepatocellular Carcinoma In Elderly Patients: final results of The Italian Cohort Of GIDEON (Global) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Oncology, 2015, 26, vi93.	0.6	1
117	Angiogenesis evaluation in locally advanced colo-rectal and gastric cancers by probe-based Confocal Laser Endomicroscopy (pCLE). <i>Annals of Oncology</i> , 2016, 27, iv48.	0.6	1
118	Evaluation of neoangiogenesis in locally advanced gastric cancer before and after neoadjuvant radiochemotherapy by probe confocal laser endomicroscopy (PCLE). <i>Annals of Oncology</i> , 2019, 30, iv80-iv81.	0.6	1
119	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	1.1	1
120	A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 804-804.	0.8	1
121	Abstract 3889: <i>RPL28</i> promoter polymorphism rs4806668 is associated with reduced survival in FOLFIRI-treated metastatic colorectal cancer patients. <i>Cancer Research</i> , 2018, 78, 3889-3889.	0.4	1
122	High-Dose Epirubicin in Locally Advanced Operable Noninflammatory Breast Cancer: A Feasibility Trial. <i>Tumori</i> , 1997, 83, 656-660.	0.6	0
123	Efficacy of Total Androgen Blockade in Metastatic Prostatic Carcinoma with Transient Hypogonadotropic Hypogonadism: A Case Report. <i>Tumori</i> , 1999, 85, 280-283.	0.6	0
124	Anthracycline dose and liver dysfunction. <i>British Journal of Cancer</i> , 1999, 79, 1943-1943.	2.9	0
125	High sensitivity of chromogranin a (CgA) as serum marker of functioning and non-functioning digestive neuroendocrine tumors. <i>Gastroenterology</i> , 2000, 118, A647.	0.6	0
126	PA.122 COMBINATION CHEMOTHERAPY (CT) WITH DOCETAXEL (D), OXALIPLATIN (O), CAPECITABINE (C) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER (AGC): PRELIMINARY RESULTS ON TOXICITY OF A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2008, 40, S119.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Preoperative Chemo-radiotherapy For T3 Stage Rectal Cancer Patients: Long-term Outcome Of Multimodality Management And Implications For Risk-adapted Treatment Strategies. International Journal of Radiation Oncology Biology Physics, 2011, 81, S371.	0.4	0
128	Pre-emptive pharmacogenetic testing implementation for chemotherapy dosage optimization: the translational experience at CRO of Aviano. Annals of Oncology, 2015, 26, vi142.	0.6	0
129	Pharmacokinetic analysis of irinotecan administered in FOLFIRI regimen in combination with bevacizumab from patients enrolled in a genotype-driven phase I study. Annals of Oncology, 2015, 26, vi133.	0.6	0
130	Final results of the gideon study according to patient etiology: The italian experience. Annals of Oncology, 2015, 26, vi93.	0.6	0
131	Polymorphism of CDH1 Promoter Is a Predictor of Clinical Outcome in Patients with Metastatic Gastric Cancer Treated with chemotherapy. Annals of Oncology, 2016, 27, iv21.	0.6	0
132	Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC). Digestive and Liver Disease, 2016, 48, e45-e46.	0.4	0
133	OC.04.7 IDENTIFICATION OF PROTEOMIC PROFILES ASSOCIATED WITH TUMOR REGRESSION GRADING IN RECTAL CANCER. Digestive and Liver Disease, 2016, 48, e85-e86.	0.4	0
134	P.09.7 PROGNOSTIC SIGNIFICANCE OF CLINICALLY METASTATIC MESORECTAL LYMPH NODES IN LOCALLY ADVANCED RECTAL CANCER TREATED BY NEOADJUVANT CHEMORADIATION: IMPLICATIONS FOR SURGICAL STRATEGIES IN RELATION TO PATHOLOGICAL RESPONSE. Digestive and Liver Disease, 2016, 48, e174.	0.4	0
135	OC.04.2 GENETIC DIVERSITY OF THE KIR/HLA SYSTEM AND OUTCOME OF PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH CHEMOTHERAPY. Digestive and Liver Disease, 2016, 48, e83-e84.	0.4	0
136	EP-1406: Cardiac sarcomas: update of an evolving multidisciplinary approach with focus on radiation therapy. Radiotherapy and Oncology, 2016, 119, S655.	0.3	0
137	The routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: An analysis of overall vs. per country results from Y-IMAGE study. Annals of Oncology, 2017, 28, v529-v530.	0.6	0
138	Determinants of oncologist's choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer. Annals of Oncology, 2018, 29, viii197-viii198.	0.6	0
139	Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. Annals of Oncology, 2018, 29, v67.	0.6	0
140	CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). Annals of Oncology, 2018, 29, viii477-viii478.	0.6	0
141	P.05.34 EVALUATION OF NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER BEFORE AND AFTER NEOADJUVANT RADIOCHEMOTHERAPY BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCLE). Digestive and Liver Disease, 2019, 51, e198.	0.4	0
142	Probe-based confocal laser endomicroscopy (pCLE) is a suitable method for extrapulmonary high grade neuroendocrine rectal carcinoma (HGNEC) evaluation. OncoTargets and Therapy, 2019, Volume 12, 4577-4583.	1.0	0
143	The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA). Annals of Oncology, 2019, 30, iv79.	0.6	0
144	Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analysis of TRIBE and TRIBE-2 studies by GONO. Annals of Oncology, 2019, 30, v218-v219.	0.6	0

#	ARTICLE	IF	CITATIONS
145	PO-0821 Long-term outcome of an organ preservation strategy following chemoradiotherapy in rectal cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S429-S430.	0.3	0
146	EP-1607 Preoperative Radiation Therapy and IORT in Retroperitoneal Soft Tissue Sarcomas. Long Term Outcome. <i>Radiotherapy and Oncology</i> , 2019, 133, S866.	0.3	0
147	Diagnostic, Prognostic, Predictive and Therapeutic Tissue Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 83-106.	0.0	0
148	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. <i>Current Clinical Pathology</i> , 2019, , 121-132.	0.0	0
149	Combined Modality Treatment for Locally Advanced Gastric Cancer: Current Evidences and New Perspectives. <i>Current Clinical Pathology</i> , 2019, , 133-145.	0.0	0
150	Surgical Strategies in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 147-152.	0.0	0
151	RPL28 Promoter polymorphism RS4806668 is associated with reduced survival in folfiri-treated metastatic colorectal cancer patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, S64-S65.	1.1	0
152	Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 46-49.	0.6	0
153	Neoadjuvant chemotherapy (CT) and postoperative chemoradiation (PCRT) in locally advanced, resectable, gastric cancer (LAGC). Preliminary results of a pilot study. <i>Journal of Clinical Oncology</i> , 2007, 25, 15078-15078.	0.8	0
154	Evidence-Based Medicine: What does it Mean and Where Are We Going?. , 2010, , 221-241.		0
155	A UGT1A1 genotype-guided dosing study of irinotecan in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus bevacizumab (BEV).. <i>Journal of Clinical Oncology</i> , 2014, 32, 562-562.	0.8	0
156	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11045-11045.	0.8	0
157	Abstract 1420: IL17F-rs9463772 independently predicts long-term outcome in locally advanced rectal cancer. , 2016, , .		0
158	An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e23502-e23502.	0.8	0
159	Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3534-3534.	0.8	0
160	Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3536-3536.	0.8	0